Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

TNFRSF11A Antikörper (N-Term)

TNFRSF11A Reaktivität: Human WB Polyclonal unconjugated
Produktnummer ABIN966946
  • Target Alle TNFRSF11A Antikörper anzeigen
    TNFRSF11A (Tumor Necrosis Factor Receptor Superfamily, Member 11a, NFKB Activator (TNFRSF11A))
    Bindungsspezifität
    • 16
    • 5
    • 4
    • 3
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 29-44, N-Term
    Reaktivität
    • 66
    • 37
    • 27
    Human
    Wirt
    Bitte anfragen
    Klonalität
    • 56
    • 23
    Polyklonal
    Konjugat
    • 44
    • 5
    • 5
    • 5
    • 3
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser TNFRSF11A Antikörper ist unkonjugiert
    Applikation
    • 57
    • 30
    • 26
    • 14
    • 14
    • 13
    • 13
    • 13
    • 6
    • 4
    • 4
    • 3
    • 2
    • 2
    • 1
    Western Blotting (WB)
    Immunogen
    A synthetic peptide corresponding to a sequence at the N-terminal of human RANK (29-44 aa), identical to the related mouse and rat sequence.
    Top Product
    Discover our top product TNFRSF11A Primärantikörper
  • Applikationshinweise
    WB: The detection limit for RANK is approximately 2.5ng/lane under non-reducing and reducing conditions.
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Rekonstitution
    0.2ml of distilled water will yield a concentration of 500µg/ml.
    Buffer
    Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4
    Konservierungsmittel
    Thimerosal (Merthiolate), Sodium azide
    Lagerung
    -20 °C
  • Theill, Boyle, Penninger: "RANK-L and RANK: T cells, bone loss, and mammalian evolution." in: Annual review of immunology, Vol. 20, pp. 795-823, (2002) (PubMed).

    Suda, Takahashi, Udagawa, Jimi, Gillespie, Martin: "Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families." in: Endocrine reviews, Vol. 20, Issue 3, pp. 345-57, (1999) (PubMed).

  • Target
    TNFRSF11A (Tumor Necrosis Factor Receptor Superfamily, Member 11a, NFKB Activator (TNFRSF11A))
    Andere Bezeichnung
    RANK (TNFRSF11A Produkte)
    Synonyme
    RANK antikoerper, RGD1563614 antikoerper, TNFRSF11A antikoerper, Ly109 antikoerper, ODFR antikoerper, OFE antikoerper, Rank antikoerper, TRANCE-R antikoerper, mRANK antikoerper, CD265 antikoerper, FEO antikoerper, LOH18CR1 antikoerper, OPTB7 antikoerper, OSTS antikoerper, PDB2 antikoerper, TRANCER antikoerper, TNF receptor superfamily member 11A antikoerper, TNF receptor superfamily member 11a antikoerper, tumor necrosis factor receptor superfamily, member 11a, NFKB activator antikoerper, Tnfrsf11a antikoerper, TNFRSF11A antikoerper
    Hintergrund
    Receptor Activator of Nuclear Factor B (RANK), also known as TRANCE Receptor, is a type I membrane protein that is expressed on the surface of osteoclasts and is involved in their activation upon ligand binding. RANK is also expressed on dendritic cells and facilitates immune signaling.RANKL (Receptor Activator for Nuclear Factor B Ligand) is found on the surface of stromal cells, osteoblasts, and T cells. By analysis of somatic cell and radiation hybrid panels, Anderson et al. (1997) mapped the RANK gene to 18q22.1.
    Pathways
    NF-kappaB Signalweg
Sie sind hier:
Kundenservice